Several Changes Made in Leadership of Allergan Eye Care

AbbVie announced several changes for its Allergan eye care business. 

Jag Dosanjh, formerly Senior Vice President, Medical Therapeutics, has been appointed to a newly created role of President, U.S. Neuroscience and Eye Care. As part of this new role, Mr. Dosanjh will continue to oversee the company’s vision care business. 

Ramin Valian, formerly Vice President, Glaucoma and Reimbursement, has been named Vice President, Eye Care, and will oversee Dry Eye/Refractive, Glaucoma, Retina, and OTC portfolios. Mr. Valian has nearly two decades of experience in the eye care industry. In 2021, he was honored with the Catalyst Award from the Glaucoma Research Foundation, recognizing his many contributions to ophthalmology. Mr. Valian will continue the company’s focus on identifying new treatments that address unmet needs and new approaches to improve access to our products.

Glen Curran, formerly Vice President, Anterior Segment, will now serve as Vice President, Botox (onabotulinumtoxinA) Therapeutic. Most recently, Mr. Curran oversaw the launch of Vuity (pilocarpine HCl ophthalmic solution) 1.25%, the latest addition to the company’s eye care portfolio, after an earlier than expected FDA approval.